Fabrication of liraglutide-encapsulated triple layer hyaluronic acid microneedles (TLMs) for the treatment of obesity

Obesity is a chronic metabolic disease that is prevalent worldwide, causing complications that affect the quality of life and longevity of humans. Currently, the low bioavailability upon subcutaneous injection of an appetite suppressant, liraglutide, and health problems in the locally injected regio...

Full description

Saved in:
Bibliographic Details
Published in:Lab on a chip 2023-05, Vol.23 (1), p.2378-2388
Main Authors: Juhng, Seorin, Song, Jieun, You, Jeongyun, Park, Jihyun, Yang, Huisuk, Jang, Mingyu, Kang, Geonwoo, Shin, Jiwoo, Ko, Hyuk Wan, Jung, Hyungil
Format: Article
Language:English
Subjects:
Animals
Bioavailability
Body weight
Diet
Diet, High-Fat
Drug delivery systems
Encapsulation
Humans
Hyaluronic acid
Hyaluronic Acid - therapeutic use
Liraglutide - pharmacology
Liraglutide - therapeutic use
Metabolic disorders
Mice
Needles
Obesity
Obesity - drug therapy
Quality of Life
Weight reduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity is a chronic metabolic disease that is prevalent worldwide, causing complications that affect the quality of life and longevity of humans. Currently, the low bioavailability upon subcutaneous injection of an appetite suppressant, liraglutide, and health problems in the locally injected region remain to be overcome. In this study, we developed a novel hyaluronic acid-based liraglutide-encapsulated triple-layer microneedle (TLM) as a painless and patient-friendly long-term drug delivery system. In contrast to previous anti-obesity microneedle approaches, this TLM is composed of three layers for complete skin insertion, protecting the encapsulated liraglutide from environmental stresses. Daily topical application of the liraglutide-loaded TLM significantly reduced body weight and improved body composition in a mouse model of high-fat diet-induced obesity. Additionally, it ameliorated diet-induced hepatic steatosis in obese mice. This novel TLM could promote a glucagon-like peptide-1 drug release system for long-term daily administration with relatively higher patient compliance compared to subcutaneous injection. The triple layer system (TLM) is a novel three layer composition dissolving microneedle which enhances drug efficacy and bioavailability, where each layer is designed to maximize the microneedle insertion and drug delivery.
ISSN:1473-0197
1473-0189
DOI:10.1039/d2lc01084d